These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16935214)

  • 21. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems.
    Reischl D; Zimmer A
    Nanomedicine; 2009 Mar; 5(1):8-20. PubMed ID: 18640078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
    Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
    Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
    Zhang SX; Ma JX
    Prog Retin Eye Res; 2007 Jan; 26(1):1-37. PubMed ID: 17074526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic application of RNA interference for hepatitis C virus.
    Watanabe T; Umehara T; Kohara M
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1263-76. PubMed ID: 17822803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice.
    He XW; Yu X; Liu T; Yu SY; Chen DJ
    Chin Med J (Engl); 2008 Mar; 121(5):439-44. PubMed ID: 18364118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
    Wang J; Shi YQ; Yi J; Ye S; Wang LM; Xu YP; He M; Kong XM
    J Dig Dis; 2008 Nov; 9(4):228-37. PubMed ID: 18959596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of RNA interference for neurological disorders.
    Sah DW
    Life Sci; 2006 Oct; 79(19):1773-80. PubMed ID: 16815477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [RNAi and a gene therapy approach to diabetic retinopathies].
    Kudo E; Shiota H
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():302-5. PubMed ID: 15999724
    [No Abstract]   [Full Text] [Related]  

  • 29. Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA.
    Inoue T; Sugimoto M; Sakurai T; Saito R; Futaki N; Hashimoto Y; Honma Y; Arai I; Nakaike S
    J Gene Med; 2007 Nov; 9(11):994-1001. PubMed ID: 17703497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
    Liu B
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters).
    Vandenbroucke RE; De Geest BG; Bonné S; Vinken M; Van Haecke T; Heimberg H; Wagner E; Rogiers V; De Smedt SC; Demeester J; Sanders NN
    J Gene Med; 2008 Jul; 10(7):783-94. PubMed ID: 18470950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.
    Koldehoff M; Beelen DW; Elmaagacli AH
    J Leukoc Biol; 2008 Aug; 84(2):561-76. PubMed ID: 18458152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes.
    Zheng X; Zhang X; Sun H; Feng B; Li M; Chen G; Vladau C; Chen D; Suzuki M; Min L; Liu W; Zhong R; Garcia B; Jevnikar A; Min WP
    Transplantation; 2006 Dec; 82(12):1781-6. PubMed ID: 17198276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A tightly regulated and reversibly inducible siRNA expression system for conditional RNAi-mediated gene silencing in mammalian cells.
    Wu RH; Cheng TL; Lo SR; Hsu HC; Hung CF; Teng CF; Wu MP; Tsai WH; Chang WT
    J Gene Med; 2007 Jul; 9(7):620-34. PubMed ID: 17486668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes.
    Khoury M; Escriou V; Courties G; Galy A; Yao R; Largeau C; Scherman D; Jorgensen C; Apparailly F
    Arthritis Rheum; 2008 Aug; 58(8):2356-67. PubMed ID: 18668557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery.
    Gary DJ; Puri N; Won YY
    J Control Release; 2007 Aug; 121(1-2):64-73. PubMed ID: 17588702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silence is golden: can RNA interference therapeutics deliver?
    Beal J
    Drug Discov Today; 2005 Feb; 10(3):169-72. PubMed ID: 15708529
    [No Abstract]   [Full Text] [Related]  

  • 39. [The application of siRNA in therapeutics].
    Mei L; Li XJ
    Sheng Li Ke Xue Jin Zhan; 2006 Oct; 37(4):347-52. PubMed ID: 17262970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eicosapentaenoic acid is anti-inflammatory in preventing choroidal neovascularization in mice.
    Koto T; Nagai N; Mochimaru H; Kurihara T; Izumi-Nagai K; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Oike Y; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4328-34. PubMed ID: 17724224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.